To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 04, 2019

Today's Rundown

Featured Story

Biogen strikes $877M Nightstar gene therapy buyout

Biogen is set to pay $877 million (€772 million) to buy Nightstar Therapeutics for its pipeline of gene therapies. The takeover will give Biogen control of clinical-phase ophthalmology assets that could get to market ahead of drugs in development at rival gene therapy shops.

Top Stories

Off-the-shelf CAR-T and gene-editing player Precision Bio files $100M IPO

Precision Bio files $100 million IPO for its off-the-shelf CAR-Ts after raising $110 million in a series B and signing a hepatitis B alliance with Gilead.

Apellis resumes phase 3 AMD trials after addressing safety issue

Apellis Pharmaceuticals has resumed dosing in phase 3 trials of its treatment for an advanced form of age-related macular degeneration (AMD). The resumption follows modifications to the production process to cut the risk of the noninfectious inflammation that triggered the halt.

Verrica’s molluscum contagiosum treatment sails through phase 3

Verrica's lead candidate met its primary endpoints in a pair of phase 3 studies testing it in the skin infection molluscum contagiosum. The treatment beat out placebo in completely clearing treatable lesions and reducing the number of lesions in both studies.

Zafgen nabs ex-Biogen executive Priya Singhal as new R&D chief

Former Biogen executive Priya Singhal has joined Zafgen as its new head of research and development. She comes to the role after helping shepherd several programs toward regulatory filings and approvals.

Resources

[Whitepaper] The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing

The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing.

[Whitepaper] How changes in drug substance processes can affect formulation

Download this whitepaper to learn more.

[Research] Maximize Pharma Marketing ROI with Digital HCP Engagement

Which HCP Touchpoints and channels are yielding the best results in today’s digital world?

[Whitepaper] Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward

White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each.

[Whitepaper] Better Market Intelligence With Smart Search

It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies.

[Whitepaper] Clinical Validation of a Powerful Immune Assay for Patient Selection

Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens.

[Whitepaper] Accelerate Time To Market Working With Industry Specialist MSP

With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events